Summit Therapeutics

10:45 AM - 11:00 AM (EDT), Tuesday, October 22, 2019 ・ 2nd Floor
Summit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers. We are currently developing new mechanism antibiotics for infections caused by C. difficile, N. gonorrhoeae and Enterobacteriaceae and are using our proprietary Discuva Platform to expand our pipeline.
Ticker:
SMMT
Exchange:
Nasdaq
Company Type:
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
United Kingdom
Year Founded:
2003
Main Therapeutic Focus:
Lead Product in Development:
Ridinilazole
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
CEO
Summit Therapeutics